There are 58 receptor tyrosine kinases (RTKs) in humans, and the epidermal growth factor receptor (EGFR, HER1, and ErbB1) is one of the first RTKs regarded as an anticancer target and brings significant improvement in the survival of NSCLC patients.90 This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.